Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
about
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to dateGene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinomaSelection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study.Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Targeting metastatic upper gastrointestinal adenocarcinomasCyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma.Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel futureTargeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsA novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.Development of Tivantinib as Treatment for Hepatocellular Carcinoma.Curcumin-induced apoptosis in human hepatocellular carcinoma j5 cells: critical role of ca(+2)-dependent pathway.Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators.Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapyThe aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma.Pathways and targets in hepatocellular carcinoma.The new golden era for radioimmunotherapy: not just for lymphomas anymore.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.Fibroblast growth factor signaling in liver carcinogenesis.Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma.Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.Drug therapy: sorafenib.Multi-omics in prognosis of hepatocellular carcinoma.Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.
P2860
Q28071589-F47B98B3-41E7-4E97-9D49-CC287DB1AC71Q28477833-D69BA433-D028-48CC-9573-4FED27D4B8BFQ30486078-3BDF511C-620E-4B99-9EAB-516C9BA669B0Q32178045-3F75C941-B797-42D7-9ED9-842AAE7B7404Q33597307-794714EA-15C0-447A-BC64-4FD76A6B7AD3Q34241371-B9137C8A-D084-4F01-BA6D-D8E54D28A592Q35000785-1BD5D2A8-8098-4F64-A872-06E677CC3231Q35248527-A89F71D9-E199-41ED-A0B2-21B05DDD2CB4Q35501246-BF9086BC-BF7E-4275-803A-A86F62736A55Q35552065-6D5DC221-B63B-461C-91F2-AB9079577FD1Q35570817-7E5DD4C0-1037-4FF1-868C-78FDD6B94B17Q35640101-C671FE7D-C16A-4138-B95C-8413B751093AQ35759606-15C747CE-A7E1-4257-9E54-756B6DB1B296Q35884134-3A9FD94B-AB31-4113-943B-D43EB4F72961Q35885030-ED2745AD-8DBA-4526-8621-21F425BC5144Q35906024-CF19535C-C830-48BD-95F1-747F5BE7C28DQ35944867-9D89C797-01AB-41AC-A698-D2DF23D8965AQ36911277-C5164463-D64C-43A5-BFBC-14DB1D4C643BQ36968841-13728B80-6676-4520-B6E5-63F5604BCCC5Q37550964-33078E08-65D7-4348-A146-96F583DBC7CEQ37606028-3370DF47-BFD3-4378-B25F-809ED3071C19Q37680185-C9D2832A-D5E1-44A5-A5D5-926C4CE3339FQ38062022-CAC2A132-6154-4F89-8872-5F2594A85C40Q38072815-E647A4F3-2A1A-4681-927F-2EDF0FF41DBCQ38155511-151CE0BF-B54C-44D4-8C03-80D98489B074Q38173739-BE25ED1C-C187-4653-A9C7-F098E9136B00Q38203285-029082BB-6B7A-4C7F-B222-4562B85F5E7CQ38796617-3373F88D-CD8C-48FD-ACAC-70C9023057C8Q38857804-D995DBB8-D20D-4A3D-81A2-745D6BDA4F20Q38999290-03B25E06-7843-43EE-AD36-3A85D4B06710Q39043607-EB6E876E-CF7F-42F8-B28E-54B9BE9389EFQ39173251-57BD7240-B23F-4386-B637-74D11E8D5FDEQ39214067-07FAF4B9-9B43-4D29-8EFB-5C4E455F5E63Q39290116-57422106-F683-47CF-8B8C-62298D33FCA9Q39499156-C2641718-2580-4BD3-BD51-207879CA4242Q41138780-EF4BEEF8-3FA3-4100-821B-387C12028ACAQ42643155-C016A641-5C6B-466F-990A-C881800778FDQ43078745-D1D836FD-E3EB-4E01-945A-0CAECE8D06BEQ43105015-60DC28A5-D294-4C70-8AC0-19B41085CD40Q45863309-4443186C-A030-4FDA-BE58-C9086DD4B7A1
P2860
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of molecularly tar ...... carcinoma: where do we go now?
@en
Development of molecularly tar ...... carcinoma: where do we go now?
@nl
type
label
Development of molecularly tar ...... carcinoma: where do we go now?
@en
Development of molecularly tar ...... carcinoma: where do we go now?
@nl
prefLabel
Development of molecularly tar ...... carcinoma: where do we go now?
@en
Development of molecularly tar ...... carcinoma: where do we go now?
@nl
P1476
Development of molecularly tar ...... carcinoma: where do we go now?
@en
P2093
Richard S Finn
P304
P356
10.1158/1078-0432.CCR-09-2084
P407
P577
2010-01-12T00:00:00Z